FindMyRecallSubscribe
Class I: serious health riskTerminated

Primus Pharmaceuticals Limbrel Recall

Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primu…

Primus Pharmaceuticals, Inc. · Scottsdale, AZ

Risk level
Class I
Reported by FDA
Feb 21, 2018
Recall ID
D-0345-2018
Check your lot numberHow we source this data

Summary

Primus Pharmaceuticals recalled Limbrel starting Jan 26, 2018. The FDA classified it as Class I (serious health risk) and published enforcement report D-0345-2018 on Feb 21, 2018. Reason: Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall. Status: Terminated.

Why it was recalled

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Product description

Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-602-16.

Lot numbers, UPCs & expiration codes

All lots within expiry.

Where it was sold

Nationwide in the USA.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0345-2018
Classification
Class I
Status
Terminated
Recall initiated
Jan 26, 2018
FDA report date
Feb 21, 2018
Quantity
135,277 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Primus Pharmaceuticals, Inc.

Original FDA data

Every field from FDA enforcement report D-0345-2018, exactly as published.

Show all FDA fields
City
Scottsdale
State
AZ
Status
Terminated
Country
United States
Event ID
79055
Address
7373 N. Scottsdale Rd., Suite B-200
Code information
All lots within expiry.
Postal code
85253
Report date
Feb 21, 2018
Product type
Drugs
Recall number
D-0345-2018
Classification
Class I
Recalling firm
Primus Pharmaceuticals, Inc.
Product quantity
135,277 bottles
Termination date
Jul 16, 2019
Reason for recall
Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Limbrel (flavocoxid 500 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-602-16.
Distribution pattern
Nationwide in the USA.
Recall initiation date
Jan 26, 2018
Initial firm notification
Press Release
Center classification date
Feb 9, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0345-2018, published Feb 21, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls